Masanori Tokumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masanori Tokumoto has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiko Tsuruya
Department of Nephrology, Nara Medical University , Kashihara
3 shared publications - Takanari Kitazono
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University , 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582
3 shared publications Hideki Hirakata
Fukuoka Renal Clinic, Fukuoka, Japan
2 shared publications- Masatomo Taniguchi
Fukuoka Renal Clinic, Fukuoka, Japan
2 shared publications - Shunsuke Yamada
Department of Medicine and Clinical Science, Graduate School of Medical Sciences Kyushu university Fukuoka Japan
2 shared publications - Toshiaki Nakano
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications
Latest Publications
- 29 August 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (12) , 1023-1031
Prevalence of hyponatremia and associated factors in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry (FKR) study
Background Hyponatremia is a common and important electrolyte disorder. However, the prevalence and factors associated with hyponatremia in patients with chronic kidney disease (CKD) are unknown. Methods We studied the factors associated with hyponatremia (< 135 mEq/L) in CKD patients registered in the Fukuoka Kidney Disease Registry (FKR) study using a logistic regression model variable selected using the variable reduction method. Results We analyzed the baseline characteristics of 4367 participants with CKD (age, 64 ± 16 years; male, 56.1%). Hyponatremia was detected in 2.0% of the patients at baseline, and multivariate logistic analysis showed that the independent factors for hyponatremia were body mass index (odds ratio [OR] 0.91; 95% confidence interval [CI] 0.85–0.97), prescription of benzodiazepine (OR 2.31; 95% CI 1.39–3.86), blood hemoglobin level (OR 0.76; 95% CI 0.65–0.88), and serum C-reactive protein level (OR 1.27; 95% CI 1.04–1.54). Conclusion The cross-sectional analysis using baseline data from the FKR study revealed independent factors associated with hyponatremia in patients with decreased kidney function. Longitudinal analyses of the FKR cohort are needed to evaluate the effects of these factors on the prognosis of hyponatremia in patients with CKD.
- 29 August 2023
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (12) , 1023-1031
Prevalence of hyponatremia and associated factors in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry (FKR) study
Background Hyponatremia is a common and important electrolyte disorder. However, the prevalence and factors associated with hyponatremia in patients with chronic kidney disease (CKD) are unknown. Methods We studied the factors associated with hyponatremia (< 135 mEq/L) in CKD patients registered in the Fukuoka Kidney Disease Registry (FKR) study using a logistic regression model variable selected using the variable reduction method. Results We analyzed the baseline characteristics of 4367 participants with CKD (age, 64 ± 16 years; male, 56.1%). Hyponatremia was detected in 2.0% of the patients at baseline, and multivariate logistic analysis showed that the independent factors for hyponatremia were body mass index (odds ratio [OR] 0.91; 95% confidence interval [CI] 0.85–0.97), prescription of benzodiazepine (OR 2.31; 95% CI 1.39–3.86), blood hemoglobin level (OR 0.76; 95% CI 0.65–0.88), and serum C-reactive protein level (OR 1.27; 95% CI 1.04–1.54). Conclusion The cross-sectional analysis using baseline data from the FKR study revealed independent factors associated with hyponatremia in patients with decreased kidney function. Longitudinal analyses of the FKR cohort are needed to evaluate the effects of these factors on the prognosis of hyponatremia in patients with CKD.
- 1 January 2023
- Published by Springer Nature
- p. 239-250
Kidney Diseases
- Open Access
- 13 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279078
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1–2 mg [131 patients], medium 3–4 mg [90 patients], high 5–8 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60–240 pg/mL) was lower in the final high-dose subgroup (216 pg/mL and 58%, respectively) than in the other subgroups (low: 149 pg/mL and 79%; medium: 149 pg/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4–10 mg/dL; P, 3.5–6.0 mg/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (p < 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical. Trial registration: This trial was registered as follows: ClinicalTrials.gov: NCT02549391 and JAPIC: JapicCTI-153013.
- 13 December 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (12) , e0279078
Open AccessPredictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism
The dosage of evocalcet required to control serum parathyroid hormone (PTH) levels varies among secondary hyperparathyroidism (SHPT) patients. This post hoc analysis evaluated the dose-dependent efficacy of evocalcet on serum intact PTH (iPTH) levels, corrected calcium (Ca) and phosphate (P) levels, and safety, in an evaluation period (week 28 to week 30) by stratifying the previous phase 3 data with the final evocalcet dosages (low 1–2 mg [131 patients], medium 3–4 mg [90 patients], high 5–8 mg [92 patients]), and identified pre-treatment patient characteristics predicting the use of higher final evocalcet dosages via univariate and multivariate logistic regression models. At the end of the study at week 30, the median serum iPTH level was higher and the achievement ratio for the target range of Japanese Society for Dialysis Therapy (60–240 pg/mL) was lower in the final high-dose subgroup (216 pg/mL and 58%, respectively) than in the other subgroups (low: 149 pg/mL and 79%; medium: 149 pg/mL and 73%, respectively). Among the three subgroups, the mean serum corrected Ca and P levels demonstrated similar trends, and similar ratio of patients achieved the target range (corrected Ca, 8.4–10 mg/dL; P, 3.5–6.0 mg/dL) from week 28 to week 30. No dose-dependent safety concerns were identified. Younger age, prior cinacalcet use, higher serum levels of iPTH and corrected Ca, procollagen type 1 N-terminal propeptide, intact fibroblast growth factor-23, and larger maximum parathyroid gland volume were significantly associated with final high-dose evocalcet (p < 0.05 in all cases). Patients requiring final high-dose evocalcet had pre-treatment characteristics indicating severe SHPT, leading to a lower final achievement rate for the target PTH levels of Japanese Society for Dialysis Therapy. Therefore, the early initiation of evocalcet treatment for SHPT is critical. Trial registration: This trial was registered as follows: ClinicalTrials.gov: NCT02549391 and JAPIC: JapicCTI-153013.
- Open Access
- 10 January 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (3) , 100408
Malnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study
- 10 January 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (3) , 100408
Open AccessMalnutrition-Inflammation Complex Syndrome and Bone Fractures and Cardiovascular Disease Events in Patients Undergoing Hemodialysis: The Q-Cohort Study
- Open Access
- 31 July 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (4) , 429-432
Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio
A 34-year-old female hemodialysis patient with an abnormal whole parathyroid hormone (PTH)/intact PTH ratio (ratio = 1.14) underwent parathyroidectomy for advanced secondary hyperparathyroidism. The abnormal PTH ratio indicated a relative increase in the serum N-terminus PTH, a new molecular form of PTH. The abnormal ratio normalized immediately after the largest parathyroid gland (PTG) was removed, proving the largest PTG as causative. An immunohistochemical analysis revealed extremely decreased expression of the calcium-sensing receptor and parafibromin in the largest PTG in comparison with the other PTGs. This case indicated the possible involvement of decreased calcium-sensing receptor and parafibromin signaling in the development of the abnormal PTH ratio.
- 31 July 2013
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 6 (4) , 429-432
Open AccessDecreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio
A 34-year-old female hemodialysis patient with an abnormal whole parathyroid hormone (PTH)/intact PTH ratio (ratio = 1.14) underwent parathyroidectomy for advanced secondary hyperparathyroidism. The abnormal PTH ratio indicated a relative increase in the serum N-terminus PTH, a new molecular form of PTH. The abnormal ratio normalized immediately after the largest parathyroid gland (PTG) was removed, proving the largest PTG as causative. An immunohistochemical analysis revealed extremely decreased expression of the calcium-sensing receptor and parafibromin in the largest PTG in comparison with the other PTGs. This case indicated the possible involvement of decreased calcium-sensing receptor and parafibromin signaling in the development of the abnormal PTH ratio.
- Open Access
- 1 September 1999
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 14 (9) , 2210-2215
Acute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane
Renal tubulointerstitium has been recognized to be a common site of immune-complexes deposition leading to tissue destruction [1–3]. However, cases of interstitial nephritis in which interstitial immune complex deposition play a major role are not commonly reported [4–14]. Most reported cases have been finally diagnosed as either collagen disease or adenovirus-type 11 infection.
- 1 September 1999
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 14 (9) , 2210-2215
Open AccessAcute interstitial nephritis with immune complex deposition and MHC class II antigen presentation along the tubular basement membrane
Renal tubulointerstitium has been recognized to be a common site of immune-complexes deposition leading to tissue destruction [1–3]. However, cases of interstitial nephritis in which interstitial immune complex deposition play a major role are not commonly reported [4–14]. Most reported cases have been finally diagnosed as either collagen disease or adenovirus-type 11 infection.